Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
47°
Light Rain
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Deciphera Pharmaceuticals Inc
(NQ:
DCPH
)
25.59
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Deciphera Pharmaceuticals Inc
< Previous
1
2
3
4
5
Next >
DCPH Stock Earnings: Deciphera Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
May 10, 2024
DCPH stock results show that Deciphera Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
April 30, 2024
Via
Benzinga
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
April 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
Earnings Scheduled For February 6, 2024
February 06, 2024
Companies Reporting Before The Bell • BP (NYSE:BP) is projected to report quarterly earnings at $1.05 per share on revenue of $53.50 billion.
Via
Benzinga
Earnings Outlook For Deciphera Pharmaceuticals
February 05, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Deciphera Pharmaceuticals
November 20, 2023
Via
Benzinga
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
April 29, 2024
U.S. stocks kicked off the week on a positive note, with all major averages edging higher in anticipation of significant events including earnings reports from tech giants like Amazon.com Inc....
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
April 29, 2024
Via
Benzinga
Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
April 29, 2024
ONO Pharmaceutical to acquire Deciphera Pharmaceuticals for $2.4B in cash. Deciphera brings specialized R&D in kinase drug discovery, commercial platforms, and a pipeline of cancer drugs including...
Via
Benzinga
Earnings Preview: Deciphera Pharmaceuticals
August 08, 2023
Via
Benzinga
The Latest Analyst Ratings for Deciphera Pharmaceuticals
May 04, 2023
Via
Benzinga
Recap: Deciphera Pharmaceuticals Q1 Earnings
May 03, 2023
Via
Benzinga
Preview: Deciphera Pharmaceuticals's Earnings
May 02, 2023
Via
Benzinga
Crude Oil Down Over 1%; Deciphera Pharmaceuticals Shares Spike Higher
April 29, 2024
Via
Benzinga
Exposures
Fossil Fuels
Why Is Mullen Automotive (MULN) Stock Up 27% Today?
April 29, 2024
Mullen Automotive stock is climbing higher on Monday with heavy trading of MULN shares alongside it joining a new voucher program.
Via
InvestorPlace
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
April 29, 2024
Via
Benzinga
Citi Just Raised Its Price Target on Shopify (SHOP) Stock
April 29, 2024
Shopify stock is on the rise Monday as shares of SHOP got an increased price target and an upgrade from Citi's analysts this morning.
Via
InvestorPlace
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
April 29, 2024
Deciphera Pharmaceuticals stock is up on Monday after DCPH investors learned of a $2.4 billion acquisition deal with ONO Pharmaceutical.
Via
InvestorPlace
Dow Surges Over 100 Points; Domino's Pizza Posts Upbeat Earnings
April 29, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion
April 29, 2024
The company is working on cancer treatments that block problematic kinases by targeting their switch-control pocket.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 29, 2024
Via
Benzinga
Deciphera Pharmaceuticals' Investigational Drug Shows Encouraging Response Rates In Rare Type Of Cancer
October 30, 2023
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT)
Via
Benzinga
Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday
October 30, 2023
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
August 21, 2023
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing.
Via
InvestorPlace
3 Under-the-Radar Biotech Stocks to Buy in 2023
August 19, 2023
All three biotech companies focus on oncology therapies.
Via
The Motley Fool
Why Shares of Deciphera Pharmaceuticals Rose This Week
August 11, 2023
The company's shares rose after the company reported second-quarter earnings.
Via
The Motley Fool
Deciphera Pharmaceuticals Sees Renewed Competitive Edge After Theseus Pan-KIT Discontinuation: Analyst
August 10, 2023
Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
August 10, 2023
Via
Benzinga
Global Payments To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Thursday
August 10, 2023
Keybanc cut the price target for i3 Verticals, Inc. (NASDAQ: IIIV) from $28 to $26. Keybanc analyst Josh Beck maintained an Overweight rating. i3 Verticals shares fell 2.9% to close at $22.76 on...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.